Higher-dose Exelon Patch approved for Alzheimer's

Share this article:
Higher-dose Exelon Patch approved for Alzheimer's
Higher-dose Exelon Patch approved for Alzheimer's
The Food and Drug Administration has approved a 13.3mg/24h dosage strength of the Exelon Patch for the treatment of patients with mild to moderate Alzheimer's disease. Approval was based on a 48-week double-blind phase of the OPTIMA study. The controlled trial targeted people with mild to moderate Alzheimer's. Compared to an older patch, patients treated with this higher dosage patch experienced statistically significant functional improvement.
Share this article:

More in Products

FDA approves weight management drug

The U.S. Food and Drug Administration has approved Contrave as a treatment for chronic weight management. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation.

PDI introduces new swab

PDI introduces new swab

PDI has debuted the PrevanticsĀ® Device Swab, a chlorhexidine gluconate/alcohol solution that has received market authorization from the U.S. Food and Drug Administration for disinfecting needleless access sites prior to ...

Oregon Freeze Dry releases Easy Meal

Oregon Freeze Dry releases Easy Meal

A new brand from Oregon Freeze Dry is designed to help long-term care and other healthcare facilities prepare for a disaster.